There are 2949 resources available
1625MO - ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
Presenter: Emanuela Palmerini
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1626MO - Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy
Presenter: Eugenie Younger
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1627MO - Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network
Presenter: Anna Maria Frezza
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1628MO - A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Presenter: Georgios Kantidakis
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1629MO - First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Presenter: Silvia Stacchiotti
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
808MO - Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Presenter: Florence Joly Lobbedez
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
813MO - Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial
Presenter: Jean-Sebastien Frenel
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
814MO - Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Presenter: Yvette Drew
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
815MO - The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
Presenter: Benoit You
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
816MO - AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)
Presenter: Fabrice Lecuru
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast